GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medigen Biotechnology 3176.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

32.45

+2.04%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 1.58bn

FY2016FY2025

Net income

−TWD 108.8m

FY2016FY2025

Free cash flow

−TWD 32.9m

FY2016FY2025

Shareholders' equity

TWD 1.55bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 1.58bnTWD 1.37bnTWD 1.16bnTWD 1.06bnTWD 3.92bnTWD 614.2mTWD 552.3mTWD 407.3mTWD 427.5mTWD 399.9m
Gross profitTWD 905.0mTWD 753.8mTWD 517.1mTWD 73.1mTWD 2.53bnTWD 228.2mTWD 221.1mTWD 79.7mTWD 87.9mTWD 54.2m
Research and developmentTWD 451.9mTWD 393.3mTWD 1.33bnTWD 1.32bnTWD 1.38bnTWD 803.4mTWD 664.2mTWD 551.9mTWD 450.4mTWD 431.2m
Operating income−TWD 105.0m−TWD 210.7m−TWD 1.23bn−TWD 1.67bnTWD 789.2m−TWD 912.2m−TWD 762.3m−TWD 762.4m−TWD 687.0m−TWD 922.7m
Net income−TWD 108.8m−TWD 204.7m−TWD 561.3m−TWD 675.9m−TWD 52.6m−TWD 337.9m−TWD 255.7m−TWD 442.7m−TWD 466.8m−TWD 568.3m
Diluted earnings per share-0.78-1.47-4.03-4.85-0.38-2.43-1.84-3.19-3.37-4.10

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 6.18bnTWD 6.71bnTWD 8.53bnTWD 9.98bnTWD 8.20bnTWD 6.15bnTWD 4.83bnTWD 4.60bnTWD 4.87bnTWD 4.82bn
Cash and short-term investments——TWD 4.59bnTWD 5.07bnTWD 3.00bnTWD 2.26bnTWD 916.1mTWD 1.17bnTWD 1.23bnTWD 1.07bn
Total liabilitiesTWD 1.46bnTWD 1.67bnTWD 3.53bnTWD 3.51bnTWD 1.77bnTWD 1.65bnTWD 2.14bnTWD 1.66bnTWD 1.69bnTWD 1.28bn
DebtTWD 421.3mTWD 1.02bnTWD 2.86bnTWD 2.77bnTWD 992.1mTWD 1.18bnTWD 1.68bnTWD 1.36bnTWD 1.39bnTWD 1.07bn
Shareholders' equityTWD 1.55bnTWD 1.58bnTWD 1.59bnTWD 2.19bnTWD 2.39bnTWD 1.82bnTWD 1.36bnTWD 1.54bnTWD 1.84bnTWD 2.20bn
Shares outstanding139m139m139m139m139m139m139m139m139m139m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsTWD 40.5mTWD 37.9m−TWD 569.4m−TWD 1.13bnTWD 517.5m−TWD 671.4m−TWD 560.2m−TWD 529.8m−TWD 455.6m−TWD 468.6m
Capital spending−TWD 73.4m−TWD 58.7m−TWD 50.9m−TWD 151.4m−TWD 144.5m−TWD 140.3m−TWD 113.8m−TWD 124.1m−TWD 110.7m−TWD 566.2m
Free cash flow−TWD 32.9m−TWD 20.8m−TWD 620.3m−TWD 1.28bnTWD 372.9m−TWD 811.7m−TWD 674.0m−TWD 653.9m−TWD 566.4m−TWD 1.03bn
Dividends paid−TWD 57.8m−TWD 54.2m−TWD 37.6m−TWD 30.0m——————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 284.7mTWD 261.5mTWD 326.7mTWD 395.7mTWD 360.8mTWD 499.4mTWD 330.6mTWD 436.6m
Gross profitTWD 170.6mTWD 137.9mTWD 185.3mTWD 163.4mTWD 201.3mTWD 355.1mTWD 162.7mTWD 230.3m
Operating incomeTWD 19.0m−TWD 67.1m−TWD 158.2m−TWD 38.2m−TWD 58.2mTWD 149.5m−TWD 52.6mTWD 4.0m
Net income−TWD 26.0m−TWD 53.1m−TWD 116.8m−TWD 56.4m−TWD 38.0mTWD 102.5m−TWD 114.0m−TWD 26.9m
Diluted earnings per share-0.19-0.38-0.84-0.41-0.270.74-0.82-0.19
Cash from operations−TWD 88.0m−TWD 91.0mTWD 136.0m−TWD 18.0m−TWD 47.0m−TWD 28.0mTWD 156.0m−TWD 28.0m
Capital spending−TWD 271.0m−TWD 103.0m−TWD 6.0m−TWD 38.0m−TWD 17.0m−TWD 10.0m−TWD 9.0m−TWD 24.0m
Free cash flow−TWD 359.0m−TWD 194.0mTWD 130.0m−TWD 56.0m−TWD 64.0m−TWD 38.0mTWD 147.0m−TWD 52.0m
Total assetsTWD 6.90bnTWD 6.95bnTWD 6.18bnTWD 6.34bnTWD 6.51bnTWD 6.62bnTWD 6.71bnTWD 6.75bn
DebtTWD 1.10bnTWD 1.12bnTWD 421.3mTWD 433.9mTWD 392.4mTWD 401.9mTWD 411.3mTWD 420.6m
Shareholders' equityTWD 1.48bnTWD 1.49bnTWD 1.55bnTWD 1.64bnTWD 1.69bnTWD 1.69bnTWD 1.58bnTWD 1.68bn

Financial ratios

Data as of 18 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin57.2%54.9%44.7%6.9%64.6%37.2%—
Operating margin-12.4%-5.6%-106.5%-157.9%20.1%-148.5%—
Net margin-6.9%-14.9%-48.5%-64.0%-1.3%-55.0%—
Return on equity-7.0%-12.9%-35.3%-30.8%-2.2%-18.6%—
Return on assets-1.8%-3.1%-6.6%-6.8%-0.6%-5.5%—
Free cash flow yield—2.0%-10.5%-19.7%13.4%-10.8%-9.0%
Revenue growth15.3%18.6%9.6%-73.1%538.8%11.2%—
Earnings growth-46.8%-63.5%-17.0%1184.6%-84.4%32.1%—
Current ratio4.68x3.96x2.05x6.40x4.62x3.24x—
Debt to equity0.27x0.26x1.66x1.15x0.35x0.56x—
Equity ratio25.1%23.6%18.7%22.0%29.2%29.5%—
Interest coverage-8.45x-2.10x-22.08x-42.25x41.39x-28.61x—
R&D as a share of sales28.6%28.6%114.7%124.9%35.1%130.8%—
Buybacks as a share of market value—0.1%0.1%-0.4%0.1%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue14.4%20.8%15.9%
Operating income-60.2%-35.1%-17.9%
Net income-45.6%-20.3%-14.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin56.1%43.5%51.6%46.8%
Operating margin-10.7%-62.2%-34.4%-60.9%
Net margin-10.6%-30.0%-20.0%-35.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-41.5-22.0-11.1-6.9-151.6-24.4-33.8-14.1-10.5-19.4
Price to sales2.93.35.44.42.013.415.615.311.527.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.